74248-66-1

Upstream product

• 124-38-9 carbon dioxide 
• 398472-14-5 4-(5methoxy-1H-benzimidazol-2-yl-sulfanylmethyl)-benzoic acid 
• 2417-72-3 Methyl 4-(bromomethyl)benzoate 
• 619-66-9 4-Carboxybenzaldehyde 
• 6232-88-8 4-bromomethylbenzoic Acid 
• 74248-99-0 methyl 2-(4-methoxycarbonylphenyl)ethyl ketone 
• 187242-82-6 (E)-4-(3-oxobut-1-en-1-yl)benzoic acid 
• 115665-93-5 (E)-methyl 4-(3-oxobut-1-en-1-yl)benzoate 
• 181214-91-5 4-((E)-3-Oxo-but-1-enyl)-benzoic acid 

Downstream Products

• 1019770-00-3 4-(3-oxobutyl)benzoyl chloride 
• 74248-67-2 4-(4-aminocarbonylphenyl)-2-butanone 
• 1019769-98-2 4-(3-oxobutyl)-N-(2,2,2-trifluoroethyl)benzamide 
• 74248-99-0 methyl 2-(4-methoxycarbonylphenyl)ethyl ketone 
• 1019770-04-7 N-cyclopropyl-4-(3-oxobutyl)benzamide 

Relevant academic research and scientific papers

Shuttle arylation by Rh(I) catalyzed reversible carbon–carbon bond activation of unstrained alcohols

The advent of transfer hydrogenation and borrowing hydrogen reactions paved the way to manipulate simple alcohols in previously unthinkable manners and circumvented the need for hydrogen gas. Analogously, transfer hydrocarbylation could greatly increase the versatility of tertiary alcohols. However, this reaction remains unexplored because of the challenges associated with the catalytic cleavage of unactivated C–C bonds. Herein, we report a rhodium(I)-catalyzed shuttle arylation cleaving the C(sp2)–C(sp3) bond in unstrained triaryl alcohols via a redox-neutral β-carbon elimination mechanism. A selective transfer hydrocarbylation of substituted (hetero)aryl groups from tertiary alcohols to ketones was realized, employing benign alcohols as latent C-nucleophiles. All preliminary mechanistic experiments support a reversible β-carbon elimination/migratory insertion mechanism. In a broader context, this novel reactivity offers a new platform for the manipulation of tertiary alcohols in catalysis.

INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS

The present invention is directed to indazole derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for e

INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS

The present invention is directed to indazole derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for e

HETEROCYCLIC COMPOUNDS USEFUL AS ANABOLIC AGENTS FOR LIVESTOCK ANIMALS

Compounds of formula (I) and pharmaceutically acceptable salts thereof are agonists at the beta-2 adrenoceptor. They are useful as feed additives for livestock animals.

Rhodium(I)-catalyzed carboxylation of aryl- and alkenylboronic esters with CO2

When the esters of arylboronic acids with 2,2-dimethylpropan-1,3-diol were treated with a catalytic amount of [Rh(OH)(cod)]2 in the presence of 1,3-bis(diphenylphosphino)propane and CsF in dioxane at 60 °C under carbon dioxide atmosphere, the benzoic acid derivatives were obtained in good yields. Reactions of alkenylboronic esters also proceeded under similar conditions to give α,β-unsaturated carboxylic acids. As these boronic esters are now easily available through coupling or direct borylation reactions, this method would be a useful method for the preparation of various functionalized aryl- and alkenyl-carboxylic acids. Copyright

Inhibitors of histone deacetylase

The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

Benzoyl 2-methyl indoles as selective PPARγ modulators

A series of selective PPARγ modulators (SPPARγMs) and their development from hPPARγ active screening leads 1 and 2 is described. SPPARγM 24 displayed robust anti-diabetic activity with an improved therapeutic window in comparison to a PPARγ full agonist in a rodent efficacy model. Routine screening for human PPAR ligands yielded compounds 1 and 2, both of which were sub-micromolar hPPARγ agonists. Synthetic modifications of these leads led to a series of potent substituted 3-benzyl-2-methyl indoles, a subset of which were noted to be selective PPARγ modulators (SPPARγMs). SPPARγM 24 displayed robust anti-diabetic activity with an improved therapeutic window in comparison to a PPARγ full agonist in a rodent efficacy model.

Inhibitors of histone deacetylase

The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

Inhibitors of histone deacetylase

The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

Process for producing p-n-alkylbenzoic acid

p-n-Alkylbenzoic acids having high purity without containing isomers are important as intermediates for liquid crystals. The p-n-alkylbenzoic acid is produced by reacting a p-formylbenzoic acid or its ester with a ketone having the formula STR1 wherein R represents a C1 -C18 n-alkyl or n-alkenyl group in the presence of a basic catalyst to obtain an unsaturated ketone compound having the formula STR2 wherein R is defined above and X represents hydrogen atom or a C1 -C6 alkyl group, and then, hydrogenating and reducing the unsaturated ketone compound to obtain the p-n-alkylbenzoic acid having the formula STR3